Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amylin’s Once-Weekly Bydureon Clears Major Cardiac Safety Hurdle

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Amylin and partners Eli Lilly and Alkermes plan to resubmit an application for once-weekly subcutaneous injectable Bydureon (exenatide) to FDA in the third quarter, after the candidate met the primary endpoint in a “thorough" QT study assessing cardiovascular risk, which is required for approval in the U.S.
Advertisement

Related Content

Lilly Sales Reps Resume Launch Of BI's Tradjenta; Judge Says FDA Regs Protect Byetta
EMA Gives Nod To Bydureon, Approves Additional Indication For Pradaxa
Failed Head-To-Head Study Clouds Bydureon's Commercial Future
Can Bydureon Bounce Back? Amylin's Proposed Cardio Safety Trial Is A Faster Option
Can Bydureon Bounce Back? Amylin's Proposed Cardio Safety Trial Is A Faster Option

Topics

Advertisement
UsernamePublicRestriction

Register

PS004774

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel